ReoPro Disease Interactions
There is 1 disease interaction with ReoPro (abciximab).
GpIIb/IIIa platelet inhibitors (applies to ReoPro) bleeding risks
Major Potential Hazard, High plausibility. Applicable conditions: Thrombocytopenia, Coagulation Defect, Hypertension, Brain/Intracranial Tumor, Thrombocytopathy, Cerebral Vascular Disorder
The use of gp11b/111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (<100,000/mm3). Thrombocytopenia, serious GI/GU bleeding, hemorrhagic retinopathy, and bleeding at the arterial access have been reported during gp11b/111a platelet inhibitor therapy. Clinical monitoring of hemoglobin and hematocrit (H/H), platelet count, prothrombin time (PT) and activated partial prothrombin time (aPTT) is recommended prior to initiation of, during and following gp11b/111a platelet inhibitor therapy.
References (9)
- Landefeld CS, Cook EF, Flatley M, Weisberg M, Goldman L (1987) "Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy." Am J Med, 82, p. 703-13
- Boehrer JD, Kereiakes DJ, Navetta FI, Califf RM, Topol EJ (1994) "Effects of profound platelet inhibition with c7E3 before coronary angioplasty on complications of coronary bypass surgery." Am J Cardiol, 74, p. 1166-70
- Kereiakes DJ, Essell JH, Abbottsmith CW, Broderick TM, Runyon JP (1996) "Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion." Am J Cardiol, 78, p. 1161
- (2001) "Product Information. Aggrastat (tirofiban)." Merck & Co., Inc
- Adgey AA (1998) "An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors." Am Heart J, 135, s43-55
- Kleiman NS (1997) "Primary and secondary safety endpoints from IMPACT II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis." Am J Cardiol, 80, b29-33
- The IMPACT-II Investigators (1997) "Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II." Lancet, 349, p. 1422-8
- The RESTORE Investigators (1997) "Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction..." Circulation, 96, p. 1445-53
- (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
Switch to consumer interaction data
ReoPro drug interactions
There are 153 drug interactions with ReoPro (abciximab).
ReoPro alcohol/food interactions
There is 1 alcohol/food interaction with ReoPro (abciximab).
Report options
More about ReoPro (abciximab)
- ReoPro consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: glycoprotein platelet inhibitors
- Breastfeeding
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Integrilin
Integrilin prevents blood clots or heart attack in people with severe chest pain and in patients ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Eptifibatide
Eptifibatide systemic is used for acute coronary syndrome, angina, heart attack, percutaneous ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.